Processa CFO granted 11,883 RSUs and options
Processa Pharmaceuticals, Inc. reported that Chief Financial Officer Russell Skibsted received a grant of 11,883 Restricted Stock Units on July 26, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Processa Pharmaceuticals, Inc. reported that Chief Financial Officer Russell Skibsted received a grant of 11,883 Restricted Stock Units on July 26, 2026. These RSUs vested immediately but will be settled later under specified conditions. After the grant he directly holds 17,323 RSUs, 16,689 common shares and stock options over 12,960 shares at a $4.9600 exercise price.
Insider Trade Summary
Grant/Award: 11,883 shares
Grant/Award
3 txns
Insider
SKIBSTED RUSSELL
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units F1, F3 | 11,883 | $0.00 | $0.00 |
| holding | Stock Options (Right to Buy) F2, F3 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 17,323 contracts (Direct);
Stock Options (Right to Buy) — 12,960 contracts (Direct);
Common Stock — 16,689 shares (Direct)
Footnotes (3)
- F1. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.
- F2. Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
- F3. Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.
Key Figures
RSU grant: 11883.0000 Restricted Stock Units
RSUs held after grant: 17323.0000 Restricted Stock Units
Stock options underlying shares: 12960.0000 shares
+3 more
6 metrics
RSU grant
11883.0000 Restricted Stock Units
Granted to the Chief Financial Officer on July 26, 2026
RSUs held after grant
17323.0000 Restricted Stock Units
Total direct RSU holdings after the reported acquisition
Stock options underlying shares
12960.0000 shares
Underlying common shares subject to stock options held directly
Stock option exercise price
$4.9600 per share
Exercise price for stock options over 12,960 underlying shares
Common stock held directly
16689.0000 shares
Direct holdings of Processa Pharmaceuticals common stock after transactions
Reverse stock split ratio
1-for-25
Reverse stock split effected on December 17, 2025, reflected in reported amounts
Key Terms
Restricted Stock Units, Stock Options (Right to Buy), 1-for-25 reverse stock split, change of control
4 terms
Restricted Stock Units financial
"Each Restricted Stock Unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy) with an exercise price of 4.9600"
1-for-25 reverse stock split financial
"Reflects the 1-for-25 reverse stock split effected by the Issuer"
change of control financial
"distributed until the earlier of termination, six months, change of control, or death"
A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity award did PCSA’s Chief Financial Officer receive in this Form 4?
Russell Skibsted, CFO of PCSA, received a grant of 11,883 Restricted Stock Units on July 26, 2026. Each RSU represents a contingent right to receive one share of Processa Pharmaceuticals common stock, increasing his overall equity-based compensation position.
How do the RSUs granted to PCSA’s CFO vest and when will they be distributed?
The 11,883 RSUs vested upon grant but are not distributed immediately. Shares will be delivered at the earlier of termination, six months after the grant date, a change of control, or the CFO’s death, creating a deferred-settlement equity award.
What stock option position does the PCSA CFO hold after the reported transactions?
After the reported transactions, the CFO holds stock options over 12,960 underlying common shares with a $4.9600 exercise price. These options vest one-third on the first anniversary of the grant, with the remaining options vesting ratably over the subsequent two years.
What is the 1-for-25 reverse stock split mentioned for PCSA in this filing?
The footnotes state that figures reflect a 1-for-25 reverse stock split effected on December 17, 2025. This corporate action consolidated every 25 existing shares into one, and the reported RSU, option, and share amounts are already adjusted for that split.
AI-generated analysis. How Rhea-AI works. Not financial advice.
